|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| C07K 16/18 | (2006.01) | ||
| G01N 33/577 | (2006.01) | ||
| A61P 25/28 | (2006.01) |
| (11) | Number of the document | 2361638 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10196705.7 |
| Date of filing the European patent application | 2006-12-08 | |
| (97) | Date of publication of the European application | 2011-08-31 |
| (45) | Date of publication and mention of the grant of the patent | 2014-01-15 |
| (46) | Date of publication of the claims translation | 2014-05-26 |
| (30) | Number | Date | Country code |
| 05027092 | 2005-12-12 | EP | |
| 06014729 | 2006-07-14 | EP | |
| 06020766 | 2006-10-02 | EP |
| (72) |
Greferath, Ruth, DE
Hickman, David, CH
Muhs, Andreas, CH
Pfeifer, Andrea, CH
Nicolau, Claude, US
|
| (73) |
AC Immune S.A.,
EPFL Innovation Park Building B, 1015 Lausanne,
CH
|
| (74) |
Marius JAKULIS - JASON,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | A-beta 1-42 atžvilgiu specifiniai monokloniniai antikūnai, pasižymintys terapinėmis savybėmis |
| A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| Payment date | Validity (years) | Amount | |
| 2024-11-21 | 19 | 347.00 EUR |
| 2025-12-08 |